 |
|
|
|
 |
 |
Investigator |
 |
Institution |
 |
Project |
 |
|
Cameron Brennan, MD |
|
Memorial Sloan-Kettering Cancer Center |
|
Identification of fusion kinases as potential therapeutic targets in malignant astrocytoma and oligodendroglioma including malignant glioma |
 |
|
Alan D'Andrea, MD |
|
Dana-Farber Cancer Institute |
|
Inhibitors of the fanconi anemia Pathway as Chemosensitizing Agents for 1,3-Bis(2-Chloroethyl)-1-Nitrosourea (BCNU) in the Treatment of Brain Tumors |
 |
|
Ingo Mellinghoff, MD |
|
University of California Los Angeles |
|
A Genome-Wide View of mTOR Dependence in GBM |
 |
|
Paul Mischel, MD |
|
Univerisity of California Los Angeles |
|
Development of a microPLC for molecular diagnosis of Glioblastoma |
 |
|
Jeremy Rich, MD |
|
Duke University |
|
Targeting DNA Damage Checkpoint Signaling in Glioma Radioresistance |
 |
|
Axel Schönthal, PhD |
|
University of Southern California |
|
Flouting COX-2: Applying the COX-2-Independent Anti-Tumor Efficacy of Celebrex to the Therapy of Glioblastoma |
 |
|
Angela van Tilborg, PhD |
|
University of Amsterdam |
|
Protein kinase target profiling and ex vivo target validation to identify efficacious inhibitors for malignant glioma |
 |
|
WK Alfred Yung, MD |
|
University of Texas/MD Anderson Cancer Center |
|
Evaluation of Small Molecule Inhibitors of the P13K/AKT Pathway |
 |
|
 |
|
|
|
 |